SCHEDULE 13G: Paradigm BioCapital Entities Disclose 5.2% Passive Stake in LENZ Therapeutics
Beneficial Ownership Disclosure
Paradigm BioCapital Advisors LP, along with affiliated entities and Senai Asefaw, M.D., has disclosed a passive beneficial ownership of 5.2% of LENZ Therapeutics, Inc.'s common stock as of March 20, 2025.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 1,419,832 shares of LENZ Therapeutics, Inc. common stock.
- This represents 5.2% of the outstanding common stock of LENZ Therapeutics, Inc.
- Paradigm BioCapital International Fund Ltd. separately reported beneficial ownership of 1,254,521 shares, representing 4.6% of the outstanding common stock.
- The filing is a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
- The beneficial ownership percentages are based on 27,542,874 shares of Common Stock outstanding as of March 12, 2025, as reported by LENZ Therapeutics, Inc. in its Form 10-K filed on March 19, 2025.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a routine disclosure of passive ownership and generally carries a neutral sentiment. It indicates an institutional investor has taken a significant stake, which can be seen as a positive signal of confidence, but the filing itself disclaims any intent to influence control.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a biotechnology-focused investment group in LENZ Therapeutics, Inc., a company likely operating in the pharmaceutical or biotechnology sector given its name and the nature of the investor. Such investments are common in the industry as funds seek exposure to promising therapeutic developments.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially signaling confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 2025-03-12 | Date as of which 27,542,874 shares of Common Stock were outstanding, as reported by the Issuer in its Form 10-K. |
| 2025-03-19 | Date LENZ Therapeutics, Inc. filed its Form 10-K with the SEC, reporting outstanding shares. |
| 2025-03-20 | Date of event which requires the filing of this Schedule 13G (crossing the 5% ownership threshold). |
| 2025-03-27 | Date the Joint Filing Agreement was executed and the Schedule 13G was signed. |
Keywords
LENZ Therapeutics, Paradigm BioCapital Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.